Panacea Biotec cash flow

Latest FY26

Cash from operations: ₹16.7cr−₹27.4 cr in FY25
Capital spending: ₹54.1cr+7.5% on FY25
Free cash flow: −₹37.4cr−₹77.7 cr in FY25
Cash from financing: −₹1.1cr−₹2.7 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	33.1	34.8	36.7	39.1
	—	6.1	3.9	3.6	4.4
	—	−4.2	−7.7	−8.4	−13.5
	—	0.0	0.0	−0.0	0.0
	—	0.0	0.0	−3.4	0.0
	—	5.3	0.8	0.1	3.5
	—	−1.3	−1.3	−38.0	−124
	—	0.0	0.0	0.0	−5.3
	—	20.9	−35.7	24.2	10.6
	—	1.3	−15.8	3.0	6.9
	—	10.4	−62.1	−4.3	81.4
	—	1.4	−1.0	−0.6	−79.9
	—	32.9	−15.6	−5.0	2.0
	—	−34.0	28.7	−17.6	−35.3
	—	−42.4	74.3	−17.6	−21.8
	—	−4.4	−7.9	−3.1	15.2
	—	0.0	0.0	0.4	0.0
	—	31.5	−6.5	40.7	−300
	—	−10.1	25.0	−10.3	−13.4
	—	3.1	0.6	−0.9	−1.2
	—	3.3	7.5	1.3	−2.6
Cash from operating activities
	−10.4	−7.4	−8.0	1.5	12.8
	—	53.0	21.8	0.9	−434
	—	45.6	13.9	2.4	−421
	—	−22.5	−40.3	0.0	0.0
	—	6.5	1.0	2.5	2.5
	—	16.7	−27.4	−0.1	−423
Cash from investing activities
	—	54.1	50.3	77.7	41.0
	—	0.0	0.0	6.7	39.5
	—	0.0	0.6	0.0	0.0
	—	0.0	0.0	0.0	0.0
	—	4.2	7.7	8.4	11.6
	—	9.4	107	72.9	420
	—	−40.5	65.0	10.2	430
Cash from financing activities
	—	3.4	0.0	0.0	0.0
	—	0.0	0.0	0.2	14.8
	—	4.4	2.7	2.6	3.6
	—	−1.1	−2.7	−2.8	−18.4
	—	−24.9	35.0	7.3	−11.5
	—	0.0	0.0	0.0	1.0
	—	−24.8	35.0	7.3	−10.5
	—	—	—	47.2	39.8
Reference items
	2.2	−4.7	−25.9	−20.1	−98.0
	0.3%	−0.7%	−4.6%	−3.6%	−21.3%
	−37.4	−37.4	−77.7	−77.8	−464
	—	−40.4	−79.1	−79.6	—
	−₹6.10	−₹6.10	−₹12.67	−₹12.69	−₹75.76
	—	−2.33×	3.14×	0.07×	12.55×
	—	6.5	1.0	2.5	2.5
	—	4.4	2.7	2.6	3.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health

₹ CrorePeersSAIPARENT HIKAL INDOCO DCAL WINDLAS HESTERBIO SOLARA SYNCOMFMcap ₹2,017 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	39.1	36.7	34.8	33.1	—
+ Finance Costs	4.4	3.6	3.9	6.1	—
+ Interest Income	-13.5	-8.4	-7.7	-4.2	—
+ Dividend Income	0.0	-0.0	0.0	0.0	—
+ Fair Value (Gains) / Losses	0.0	-3.4	0.0	0.0	—
+ Unrealised FX (Gain) / Loss	3.5	0.1	0.8	5.3	—
+ Other Non-cash Items	-124.2	-38.0	-1.3	-1.3	—
+ Other — Cash Effects are Investing / Financing	-5.3	0.0	0.0	0.0	—
Changes in Working Capital
+ Inventories	10.6	24.2	-35.7	20.9	—
+ Trade Receivables — Current	6.9	3.0	-15.8	1.3	—
+ Other Financial Assets — Current	81.4	-4.3	-62.1	10.4	—
+ Other Financial Assets — Non-current	-79.9	-0.6	-1.0	1.4	—
+ Other Current Assets	2.0	-5.0	-15.6	32.9	—
+ Other Non-current Assets	-35.3	-17.6	28.7	-34.0	—
+ Trade Payables — Current	-21.8	-17.6	74.3	-42.4	—
+ Other Financial Liabilities — Current	15.2	-3.1	-7.9	-4.4	—
+ Other Financial Liabilities — Non-current	0.0	0.4	0.0	0.0	—
+ Other Current Liabilities	-299.8	40.7	-6.5	31.5	—
+ Other Non-current Liabilities	-13.4	-10.3	25.0	-10.1	—
+ Provisions — Current	-1.2	-0.9	0.6	3.1	—
+ Provisions — Non-current	-2.6	1.3	7.5	3.3	—
Cash from Operating Activities
Profit Before Tax (per I/S)	12.8	1.5	-8.0	-7.4	-10.4
+ Total Adjustments (incl. Working Capital)	-433.8	0.9	21.8	53.0	—
Cash from Operations (pre-tax)	-421.0	2.4	13.9	45.6	—
+ Other Inflows / (Outflows) — Operating	0.0	0.0	-40.3	-22.5	—
+ Income Taxes Paid	2.5	2.5	1.0	6.5	—
Cash from Operating Activities	-423.5	-0.1	-27.4	16.7	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	41.0	77.7	50.3	54.1	—
+ Disp of Fixed Assets	39.5	6.7	0.0	0.0	—
+ Disp of Investment Property	0.0	0.0	0.6	0.0	—
+ Dividends Received — Investing	0.0	0.0	0.0	0.0	—
+ Interest Received — Investing	11.6	8.4	7.7	4.2	—
+ Other Inflows / (Outflows) — Investing	420.2	72.9	107.0	9.4	—
Cash from Investing Activities	430.3	10.2	65.0	-40.5	—
Cash from Financing Activities
+ Proceeds from Borrowings	0.0	0.0	0.0	3.4	—
+ Repayment of Borrowings	14.8	0.2	0.0	0.0	—
+ Interest Paid	3.6	2.6	2.7	4.4	—
Cash from Financing Activities	-18.4	-2.8	-2.7	-1.1	—
Net Changes in Cash (pre-FX)	-11.5	7.3	35.0	-24.9	—
+ Effect of FX Rate Changes on Cash	1.0	0.0	0.0	0.0	—
Net Changes in Cash	-10.5	7.3	35.0	-24.8	—
Closing Cash	39.8	47.2	—	—	—
Reference Items
EBITDA	-98.0	-20.1	-25.9	-4.7	2.2
EBITDA Margin %	-21.30	-3.59	-4.63	-0.73	0.33
Free Cash Flow (CFO − Capex)	-464.4	-77.8	-77.7	-37.4	-37.4
Free Cash Flow to Equity	—	-79.6	-79.1	-40.4	—
Free Cash Flow per Basic Share	-75.76	-12.69	-12.67	-6.10	-6.10
Cash Flow to Net Income	12.55	0.07	3.14	-2.33	—
Cash Paid for Taxes	2.5	2.5	1.0	6.5	—
Cash Paid for Interest	3.6	2.6	2.7	4.4	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.